Budget 2025, Jan. 31 -- The Nifty Pharma Index though is down 9%,during year to date in January, with corrections in the markets Nevertheless expectations remain high for the pharma sector as a whole and outlook for Contract drug Research and Manufacturing is looked at with optimism
Leaders as Jonathan Hunt, MD and CEO of Syngene International said that I am going to wait and see what's in the budget, but in general, I think we have seen the the government in India over the recent years pay more attention to our industry, particularly the Pharmaceutical industry with the PLI scheme. They've done quite a lot in recent years and can do more for Contract Research (CDMO business . By tradition, it's been more focused on the manufacturing gen...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.